Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Eating legumes at high amounts appears to be cardioprotective, resulting in lower risks of cardiovascular disease and coronary heart disease, according to a study.

Eating one egg per day has no impact on BP, HbA1c

Regardless of overweight or obesity status, intake of one egg per day does not seem to affect blood pressure (BP) or glycated haemoglobin (HbA1c) levels, a recent study has found.

Does cerebral embolic protection reduce stroke risk post-TAVR?

The use of a cerebral embolic protection (CEP) device did not reduce the risk of periprocedural stroke in patients undergoing transcatheter aortic valve replacement (TAVR), according to results of the PROTECTED TAVR study presented at TCT 2022.

27 Oct 2022

Higher SBP-TTR linked to reduced risks of adverse kidney, CV events in hypertension

In adult patients with hypertension, higher time-in-target range (TTR) for systolic blood pressure (SBP) appears to be associated with lower risks of unfavourable kidney and cardiovascular events, according to a study.

Microfluidic PCR platform promises early detection of neonatal sepsis

A digital microfluidic (DMF) device can reduce time to detect bacteria by as much as 9 hours, speeding up the diagnosis of neonatal sepsis, as shown in a study presented at IDWeek 2022 in Washington, DC, US.

Does obesity raise risk of hospitalization IBD patients?

Obesity does not increase the likelihood of hospitalization among biologic-treated patients with inflammatory bowel disease (IBD), suggests a recent study.

27 Oct 2022

B/F/TAF safe, effective in adults with high HIV-1 RNA, low CD4 count

Adults with a high baseline HIV-1 RNA or low CD4 count may benefit from initial treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), which has been shown to be safe and efficacious over 5 years of follow-up in a study presented at the ID Week 2022 Virtual Conference.

27 Oct 2022

Exercise improves quality of life of patients with advanced liver disease

Exercise interventions may result in positive outcomes on muscular or cardiorespiratory fitness and quality of life in patients with advanced liver disease, suggest the results of a systematic review.

27 Oct 2022

Phase II data shows treatment potential of litifilimab for CLE

In part B* of the two-part 16-week LILAC study, the anti-BDCA2** antibody litifilimab reduced skin disease activity in individuals with cutaneous lupus erythematosus (CLE).

Ridinilazole triggers clinical response in CDI, inhibits recurrence